PRN Archives - Page 3 of 8

Developments

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

An investigator for Profound Medical (NASDAQ:PROF; TSX:PRN) presented four-year follow-up data from the TACT clinical study with Profound’s TULSA-PRO device that continue to demonstrate durable and stable safety and...

September 26, 2022

Developments

Profound Medical realigns commercial organization to support continued growth

Profound Medical (NASDAQ:PROF; TSX:PRN) has changed its management team and structure to further position the company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed...

September 15, 2022

Developments

Cowen sees continued demand for Profound’s TULSA-PRO after AUA2022

“We continue to gain confidence in the disruptive potential of Profound Medical’s (NASDAQ:PROF; TSX:PRN) transurethral directional thermal ultrasound ablation treatment for prostate cancer, TULSA-PRO,” writes Cowen...

May 20, 2022

Developments

Profound Medical insiders add to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...

May 19, 2022

Developments

Profound Medical’s TULSA-PRO front and center at AUA2022

The American Urological Association’s 2022 annual meeting featured multiple clinical presentations and product demonstrations of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO to effectively and safely ablate...

May 18, 2022

Developments

Profound Medical nearly doubles Q1 revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) posted revenue of $1.4-million in the first quarter, up 92%, from $711,000 in the year earlier quarter. In the latest period, the company generated $1.02-million from recurring...

May 9, 2022

Developments

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

A key opinion leader highlighted the numerous technology advancements and clinical advantages of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO treatment of prostate diseases at a company hosted clinical education...

May 2, 2022

Developments

Profound Medical CEO adds to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired a total of 60,599 shares of Profound on the open market at a cost of $497,180 (U.S.). According to a filing with SEDI, Dr. Menawat...

March 11, 2022

Developments

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

Profound Medical (NASDAQ:PROF; TSX:PRN) treated the first patients in the Level 1 CAPTAIN trial comparing the TULSA procedure (performed with its TULSA-PRO system) against radical prostatectomy (RP). The prospective...

January 18, 2022

Executive Moves

Global medical device executive Kenneth Knudson joins Profound as CCO

Profound Medical (NASDAQ:PROF; TSX:PRN) appointed accomplished global medical device industry veteran, Kenneth Knudson, as chief commercial officer to lead Profound’s worldwide sales, marketing and reimbursement...

January 5, 2022

Tag - PRN

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

Profound Medical realigns commercial organization to support continued growth

Cowen sees continued demand for Profound’s TULSA-PRO after AUA2022

Profound Medical insiders add to holdings

Profound Medical’s TULSA-PRO front and center at AUA2022

Profound Medical nearly doubles Q1 revenue

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

Profound Medical CEO adds to holdings

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

Global medical device executive Kenneth Knudson joins Profound as CCO

General

More